Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
Sponsor
Innovative Medical (Industry)
Overall Status
Completed
CT.gov ID
NCT00383396
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- pts with symptomatic pterygia unresponsive to palliative treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dr. Schechter | Boynton Beach | Florida | United States | 33426 |
Sponsors and Collaborators
- Innovative Medical
Investigators
- Principal Investigator: Barry Schechter, MD, Florida Eye Microsurgical Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00383396
Other Study ID Numbers:
- 1963
First Posted:
Oct 3, 2006
Last Update Posted:
Feb 13, 2007
Last Verified:
Feb 1, 2007